Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity

The Journal of Urology
G D GrossfeldP R Carroll

Abstract

We compare the biological phenotype of recurrent prostatic tumors after definitive local therapy (radiation or radical prostatectomy) with that of the same tumors before treatment. Cellular proliferation (Ki-67 labeling index), p53 nuclear reactivity and bcl-2 immunoreactivity were determined in pretreatment and posttreatment tumor specimens from 13 patients with local tumor recurrence following radiation, and in 18 patients with local tumor recurrence following radical prostatectomy. Mean Ki-67 labeling index increased approximately 2-fold in locally recurrent tumors after radiation (10.5 versus 5.6%, p=0.0008) or surgery (6.0 versus 3.2%, p=0.0025) when compared with pretreatment tumors. We noted p53 nuclear reactivity in a significantly higher proportion of recurrences than in pretreatment tumors following radiation (54 versus 8%, p=0.032) and surgery (39 versus 5%, p=0.022). Although bcl-2 immunoreactivity was also seen in a higher proportion of recurrent tumors, this difference did not reach statistical significance for either radiation or surgery. Recurrent tumors following either radiation or surgery differ significantly from the corresponding pretreatment tumors with respect to cellular proliferation and p53 nuclear rea...Continue Reading

References

Feb 1, 1990·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H PourquierH Pujol
Sep 30, 1994·International Journal of Radiation Oncology, Biology, Physics·V S KavadiA Pollack
Jul 1, 1995·Mutation Research·T D TlstyA White
Oct 20, 1993·Journal of the National Cancer Institute·N M NavoneC J Conti
Feb 7, 1997·Cell·A G PaulovichL H Hartwell

❮ Previous
Next ❯

Citations

Dec 2, 2010·JAMA : the Journal of the American Medical Association·Julia H HayesPamela M McMahon
Nov 3, 2001·Pathology Oncology Research : POR·S Karaburun PakerM Baykara
Oct 10, 2001·The Urologic Clinics of North America·S E Schild, T M Pisansky
Jun 14, 2002·International Journal of Radiation Oncology, Biology, Physics·Mark A RitterBret M Verhoven
Apr 16, 2003·International Journal of Radiation Oncology, Biology, Physics·Charles J RosserLouis L Pisters
Jan 5, 2000·BJU International·J L BurtonJ B Anderson
Jan 29, 2013·BMC Urology·Diego A PalaciosCharles J Rosser
Jun 4, 2004·Expert Opinion on Biological Therapy·Kim N Chi, Martin E Gleave
Jul 13, 2005·Mayo Clinic Proceedings·Thomas M Pisansky
Dec 14, 2004·Free Radical Biology & Medicine·Bryan HusbeckSusan J Knox
Jul 4, 2006·International Journal of Radiation Oncology, Biology, Physics·Li-Yan KhorAlan Pollack
Jun 11, 1999·The Urologic Clinics of North America·G S PalapattuA S Belldegrun
Apr 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David I QuinnRobert L Sutherland
Aug 14, 2001·São Paulo Medical Journal = Revista Paulista De Medicina·F L HeringM Srougi
Mar 11, 2003·Prostate Cancer and Prostatic Diseases·A ErbersdoblerH Huland
Mar 29, 2003·Prostate Cancer and Prostatic Diseases·G P BromfieldR G Bristow
Mar 1, 2010·Experimental and Therapeutic Medicine·Srikumar ChakravarthiNagaraja Lee
Oct 15, 2020·Andrology·Maria Yu KonoshenkoPavel P Laktionov
Jun 22, 2021·Proteomics. Clinical Applications·Natalie KurganovsThomas Kislinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.